Moxifloxacin Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

72 Suppliers, 24 USDMF, 21 CEP/COS, 5 JDMF, 17 EU WC, 14 KDMF, 19 NDC API, 44 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

4 Suppliers

4 Suppliers

DOSSIERs // Finished Dosage Forms

74 Dossiers, 28 FDA Orange Book, 14 Europe, 15 Canada, 2 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 31 Kerry, 27 Roquette, 13 Seppic, 12 Sigachi Industries, 12 Gangwal Healthcare, 12 BASF, 11 Microlex e.U, 10 Corel Pharma Chem, 10 Gangwal Chemicals, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 Actylis, 7 SPI Pharma, 7 Ideal Cures Pvt Ltd, 6 Nanjing Well Pharmaceutical, 6 DFE Pharma, 6 Lonza Capsugel, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 5 Prachin Chemical, 4 Vasa Pharmachem, 4 Ingredion Pharma Solutions, 3 Boai NKY Pharmaceuticals Ltd, 3 Kima Chemical, 3 Pharmatrans-Sanaq, 3 Jai Radhe Sales, 2 Alcedo Pharmachem, 2 Rochem International Inc, 2 Nomisma Healthcare, 2 The Dow Chemical Company, 2 Seqens, 2 Clariant, 2 DKSH, 1 Nanjing Bold Chemical, 1 Minakem, 1 Zhejiang Huakang Pharmaceutical, 1 Ulanqab Kema New Material, 1 Finar, 1 Curia, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Huzhou Sunflower Pharmaceutical Co. Ltd, 1 Avesta Pharma, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Aeon Procare, 1 Shanghai Welltone Material Technology Co., Ltd, 1 ACG Worldwide, 1 NEWEDGE Overseas, 1 Pharm-RX Chemical, 1 Chynops Pharma, 1 Qualicaps

EXCIPIENTS BY APPLICATIONS

68 Fillers, Diluents & Binders, 51 Coating Systems & Additives, 32 Disintegrants & Superdisintegrants, 29 Controlled & Modified Release, 28 Direct Compression, 23 Thickeners and Stabilizers, 22 Lubricants & Glidants, 21 Solubilizers, 20 Film Formers & Plasticizers, 18 Parenteral, 17 Granulation, 14 Topical, 13 Co-Processed Excipients, 12 Taste Masking, 10 Chewable & Orodispersible Aids, 8 Emulsifying Agents, 8 API Stability Enhancers, 5 Rheology Modifiers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Soft Gelatin

GLOBAL SALES INFORMATION

36 US Medicaid Prescriptions, 4 Finished Drug Prices

MARKET PLACE

28 APIs, 1 DOSSIERS // FDF

PATENTS

2 US Patents, 18 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 2 EDQM Standards, 1 USP Standards, 3 Other Ref. Standards

DIGITAL CONTENT

18 News

18 News

Information, Expiry, & Status of FDA Orange Book Exclusivities covering Moxifloxacin Hydrochloride

Moxifloxacin Hydrochloride

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

72 Suppliers

24 USDMF

21 CEP/COS

5 JDMF

17 EU WC

14 KDMF

19 NDC API

44 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

4 Suppliers

DOSSIERs // Finished Dosage Forms

74 Dossiers

28 FDA Orange Book

14 Europe

15 Canada

2 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

Suppliers

31 Kerry

27 Roquette

13 Seppic

12 Sigachi Industries

12 Gangwal Healthcare

12 BASF

11 Microlex e.U

10 Corel Pharma Chem

10 Gangwal Chemicals

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

8 Actylis

7 SPI Pharma

7 Ideal Cures Pvt Ltd

6 Nanjing Well Pharmaceutical

6 DFE Pharma

6 Lonza Capsugel

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

5 Prachin Chemical

4 Vasa Pharmachem

4 Ingredion Pharma Solutions

3 Boai NKY Pharmaceuticals Ltd

3 Kima Chemical

3 Pharmatrans-Sanaq

3 Jai Radhe Sales

2 Alcedo Pharmachem

2 Rochem International Inc

2 Nomisma Healthcare

2 The Dow Chemical Company

2 Seqens

2 Clariant

2 DKSH

1 Nanjing Bold Chemical

1 Minakem

1 Zhejiang Huakang Pharmaceutical

1 Ulanqab Kema New Material

1 Finar

1 Curia

1 Qianhao Chemical (Hebei) Co., Ltd

1 Huzhou Sunflower Pharmaceutical Co. Ltd

1 Avesta Pharma

1 Shijiazhuang Huaxu Pharmaceutical

1 Aeon Procare

1 Shanghai Welltone Material Technology Co., Ltd

1 ACG Worldwide

TABLET;ORAL - EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons